First Sabrepoint Capital Management LP Sells 210,000 Shares of OmniAb, Inc. (NASDAQ:OABI)

First Sabrepoint Capital Management LP decreased its holdings in OmniAb, Inc. (NASDAQ:OABI - Free Report) by 11.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,665,000 shares of the company's stock after selling 210,000 shares during the quarter. OmniAb makes up 2.0% of First Sabrepoint Capital Management LP's investment portfolio, making the stock its 18th biggest holding. First Sabrepoint Capital Management LP owned approximately 1.41% of OmniAb worth $7,043,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of OABI. CWC Advisors LLC. bought a new position in OmniAb during the 3rd quarter worth approximately $54,000. Walleye Capital LLC bought a new stake in OmniAb in the third quarter worth approximately $61,000. Intech Investment Management LLC bought a new position in shares of OmniAb during the 3rd quarter worth approximately $70,000. China Universal Asset Management Co. Ltd. increased its stake in shares of OmniAb by 64.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company's stock valued at $96,000 after acquiring an additional 8,909 shares in the last quarter. Finally, Palumbo Wealth Management LLC lifted its position in shares of OmniAb by 12.5% during the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company's stock valued at $104,000 after acquiring an additional 2,744 shares during the period. 72.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have weighed in on OABI shares. HC Wainwright reaffirmed a "buy" rating and issued a $11.00 price target on shares of OmniAb in a research note on Thursday, November 14th. Benchmark reissued a "buy" rating and issued a $8.00 price objective on shares of OmniAb in a research note on Thursday, November 14th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $7.00 target price on shares of OmniAb in a research report on Friday, August 16th.

OmniAb Stock Down 0.2 %

OABI stock traded down $0.01 during mid-day trading on Tuesday, reaching $4.05. 277,349 shares of the company traded hands, compared to its average volume of 503,444. The stock has a market cap of $571.94 million, a price-to-earnings ratio of -6.55 and a beta of -0.14. OmniAb, Inc. has a fifty-two week low of $3.56 and a fifty-two week high of $6.72. The firm's 50 day moving average price is $4.04 and its 200 day moving average price is $4.20.

OmniAb Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.